DTIL (Precision BioSciences) LT-Debt-to-Total-Asset: 0.03 (As of Mar. 2026)

What is Precision BioSciences LT-Debt-to-Total-Asset?

Precision BioSciences DTIL -4.37% 50 LT-Debt-to-Total-Asset is 0.03 as of Mar. 2026. GuruFocus rates DTIL with a GF Score™ of 50/100 and a GF Value™ of $1.83 (Significantly Overvalued). The stock has 5 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Precision BioSciences's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.03.

Precision BioSciences's long-term debt to total assets ratio declined from Mar. 2025 (0.23) to Mar. 2026 (0.03). It may suggest that Precision BioSciences is progressively becoming less dependent on debt to grow their business.

Precision BioSciences (NAS:DTIL) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Precision BioSciences LT-Debt-to-Total-Asset Related Terms

Precision BioSciences LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Precision BioSciences's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Precision BioSciences LT-Debt-to-Total-Asset Chart

Precision BioSciences Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.03

0.10

0.05

0.21

0.18

Precision BioSciences Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.23	0.26	0.30	0.18	0.03

50GF Score

Precision BioSciences Inc DTIL

LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Precision BioSciences LT-Debt-to-Total-Asset Calculation

Precision BioSciences's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )	/	Total Assets (A: Dec. 2025 )
	=	27.301	/	154.416
	=	0.18

Precision BioSciences's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )	/	Total Assets (Q: Mar. 2026 )
	=	4.49	/	143.891
	=	0.03

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →

What does a LT-Debt-to-Total-Asset of 0.03 mean?

Precision BioSciences (DTIL) has a LT-Debt-to-Total-Asset of 0.03 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Precision BioSciences and its competitors.

Is Precision BioSciences' LT-Debt-to-Total-Asset too high?

Precision BioSciences' current LT-Debt-to-Total-Asset is 0.03. Overall, Precision BioSciences has a GF Score™ of 50/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.

How does Precision BioSciences' LT-Debt-to-Total-Asset compare to NBP and HUMA?

Precision BioSciences' LT-Debt-to-Total-Asset of 0.03 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good LT-Debt-to-Total-Asset for a Biotechnology company?

A good LT-Debt-to-Total-Asset depends on the Biotechnology industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high LT-Debt-to-Total-Asset mean?

A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Precision BioSciences and its competitors. Precision BioSciences's current LT-Debt-to-Total-Asset is 0.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Precision BioSciences stock overvalued right now?

Based on GuruFocus' analysis, Precision BioSciences (DTIL) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.83, compared to a current price of $8.77 — trading 379% above its estimated fair value. The current LT-Debt-to-Total-Asset is 0.03. Precision BioSciences' overall GF Score™ is 50/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is LT-Debt-to-Total-Asset calculated?

LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Precision BioSciences (DTIL), the current LT-Debt-to-Total-Asset is 0.03 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Precision BioSciences (DTIL) Overvalued in 2026?

Based on GuruFocus' analysis, Precision BioSciences stock appears to be overvalued. The current stock price of $8.77 is trading 379% above its estimated GF Value™ of $1.83. GuruFocus considers Precision BioSciences to be Significantly Overvalued.

Key valuation signals for DTIL:

LT-Debt-to-Total-Asset: 0.03
GF Value™: $1.83 vs. price of $8.77 (379% above fair value)
GF Score™: 50/100 with 5 warning signs

No single metric tells the full story. See the DTIL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Precision BioSciences Business Description

Industry Healthcare Biotechnology

Comparable Companies NBP HUMA ORMP EQ PLX OKUR ANTX ARCT MDWD UNCY VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Other Exchanges PBS0:Germany

Address 302 East Pettigrew Street, Dibrell Building, Suite A-100, Durham, NC, USA, 27701

Website https://www.precisionbiosciences.com

Precision BioSciences Inc clinical stage gene editing company utilizing its proprietary ARCUS platform to concurrently develop two clinical-stage in vivo gene editing therapies. The ARCUS platform is used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome, e.g. viral DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single adeno-associated virus ("AAV")).

50GF Score

Get the complete analysis for DTIL

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$8.77

Price

$1.83

GF Value

View DTIL Analysis

See LT-Debt-to-Total-Asset data for all stocks →